Head-to-head evidence
AV-101 vs Onfasprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Onfasprodil
Developed by Novartis
NCT03756129 · Phase 2 · completed
Participants were randomized and blinded to MIJ821, placebo, or ketamine, but the 70-person study was small and spread across six treatment groups. The clinical primary endpoint was met at 24 hours for both pooled MIJ821 dose groups versus placebo, with statistically significant MADRS score differences, but the limited sample size supports moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-101's landscape · Onfasprodil's landscape